Ask AI
Heart Failure SGLT2i Master Class

CE / CME

Arm-in-Arm With Heart Failure Experts: A Master Class in Optimizing Heart Failure Treatment With SGLT2 Inhibitors

Physician Assistants/Physician Associates: 1.25 AAPA Category 1 CME credits

Nurse Practitioners/Nurses: 1.25 Nursing contact hours

Physicians: maximum of 1.25 AMA PRA Category 1 Credits

Released: October 23, 2025

Expiration: October 22, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Your patient is a 68-yr-old man with hypertension, CKD, and a recent diagnosis of HFrEF (EF 30%) made 2 wk ago after an outpatient echocardiogram. He presents to the ED with worsening dyspnea. His vital signs are within the normal range. His oxygen saturation is normal on 2L oxygen via nasal cannula. He has an elevated JVP and 2+ lower extremity edema. He responds well to intravenous diuretic therapy and is now euvolemic, eating well, and ambulating on the ward. His outpatient ACE inhibitor was switched to an ARNI, and he was started on a low-dose β-blocker. When would you consider initiation of an SGLT2 inhibitor?

2.

Which of the following best summarizes the evidence from major randomized clinical trials regarding the use of SGLT2 inhibitors in patients with heart failure, regardless of ejection fraction?

3.

A 74-yr-old woman with a history of hypertension and obesity presents with increasing fatigue and exertional dyspnea over the past 3 mo. She has CKD with an eGFR of 48 mL/min/1.73 m². She does not have diabetes mellitus. She is on amlodipine and hydrochlorothiazide. Her echocardiogram demonstrates an LVEF of 56%, mild left atrial enlargement, and moderate diastolic dysfunction. Her NT-proBNP level is elevated. She is felt to have NYHA class II functional status. Which of the following is the most appropriate approach as it relates to an SGLT2 inhibitor?